Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 4/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ESRRB | O95718 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599449 | 1.00 | BRAF (0.46) | BRAFRAF1GBA1MCHR1DRD2 | |
| SCHEMBL5408938 | 0.93 | BRAF (0.46) | BRAFRAF1GBA1MCHR1DRD2 | |
| SCHEMBL5408934 | 0.93 | BRAF (0.46) | BRAFRAF1GBA1MCHR1DRD2 | |
| SCHEMBL6606901 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL6606892 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL5107258 | 0.79 | DRD2 (0.43) | BRAFGBA1DRD2DRD3HRH3 | |
| SCHEMBL5412381 | 0.73 | NPC1 (0.32) | — | |
| SCHEMBL5412374 | 0.73 | NPC1 (0.32) | — | |
| SCHEMBL5405915 | 0.73 | BCHE (0.56) | HRH3 | |
| SCHEMBL5405919 | 0.73 | BCHE (0.56) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297694-B2 | Pyridylfurans and pyrroles as Raf kinase inhibitors | SMITHKLINE BEECHUM P.L.C. (GB) | 2007-11-20 | — | — | US | disclosed |
| US-20040254186-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-12-16 | — | — | US | disclosed |
| EP-1432697-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003022833-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254186-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | BRAF, ARAF, RAF1 | BRAF 1/4885RAF1 3/4885GBA1 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.